EPISODE · May 23, 2026 · 11 MIN
Gilead Breaks Decades-Long Drought With First Hepatitis Delta Drug, Now Faces Hunt For 60,000 Undiagnosed Patients
from 1nessAgency Insights
Gilead Sciences secured a rare commercial advantage on May 22, 2026, when the FDA approved Hepcludex (bulevirtide-gmod) as the first treatment for chronic hepatitis delta virus infection in adults—ending a decades-long therapeutic drought for a disease that accelerates liver failure faster than hepa
What this episode covers
Gilead Sciences secured a rare commercial advantage on May 22, 2026, when the FDA approved Hepcludex (bulevirtide-gmod) as the first treatment for chronic hepatitis delta virus infection in adults—ending a decades-long therapeutic drought for a disease that accelerates liver failure faster than hepa
NOW PLAYING
Gilead Breaks Decades-Long Drought With First Hepatitis Delta Drug, Now Faces Hunt For 60,000 Undiagnosed Patients
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m